Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.

Fifi A, Raphael BP, Terreri B, Uddin S, Kaufman SS

Journal of pediatric gastroenterology and nutrition22 Aug 2023Cited by 5 (Europe PMC)

PMID37889619PMCIDPMC10583903DOI10.1097/mpg.0000000000003922PepBankPUB-37889619

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In children receiving teduglutide, BSFS scores changed by -1.8 and -2.2 from baseline at weeks 12 and 24, respectively.
In plain wordsIn children receiving teduglutide, stool consistency scores decreased from baseline at weeks 12 and 24.
Peptide
Teduglutide
Outcome
DecreaseBSFS score at weeks 12 and 24
Study
n = 87
Analysis
Primary
Outcome group
Stool Consistency · Gastrointestinal
Studied dose
Dose not stated
Measurements
BSFS change
−1.8 points
week 12
SE
0.26 points
week 12
BSFS change
−2.2 points
week 24
SE
0.27 points
week 24
Source sentences
Summary
Among the total teduglutide group (n = 87), there were significant changes from baseline to weeks 12 and 24 in mean (standard error) Bristol Stool Form Scale (BSFS) score [-1.8 (0.26; P < 0.0001) and -2.2 (0.27; P < 0.0001), respectively]
2 context sentences(design, population, supporting numbers)
Summary · context
Data from 2 open-label, multicenter, phase 3 pediatric SBS-IF clinical trials of teduglutide (NCT01952080 and NCT02682381) were pooled where possible.
Summary · context
The primary objective was to evaluate the change in stool consistency, frequency, and volume from baseline to weeks 12 and 24 of treatment in patients who received any teduglutide dose from both studies ("total teduglutide").
Report a problemFND-3788961901
02HumanNon-randomized trialEfficacy outcome
In children receiving teduglutide, PN/IV volume changed by -16.9 and -20.1 mL/kg/day from baseline at weeks 12 and 24, respectively.
In plain wordsIn children receiving teduglutide, intravenous support volume decreased from baseline at weeks 12 and 24.
Peptide
Teduglutide
Outcome
DecreasePN/IV volume at weeks 12 and 24
Study
n = 87
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
PN/IV change
−16.9 mL/kg/day
week 12
SE
1.7 mL/kg/day
week 12
PN/IV change
−20.1 mL/kg/day
week 24
SE
2.3 mL/kg/day
week 24
Source sentences
Summary
parenteral nutrition and/or intravenous fluid (PN/IV) volume [-16.9 (1.7; P < 0.0001) and -20.1 (2.3; P < 0.0001) mL/kg/day, respectively]
2 context sentences(design, population, supporting numbers)
Summary · context
Data from 2 open-label, multicenter, phase 3 pediatric SBS-IF clinical trials of teduglutide (NCT01952080 and NCT02682381) were pooled where possible.
Summary · context
The primary objective was to evaluate the change in stool consistency, frequency, and volume from baseline to weeks 12 and 24 of treatment in patients who received any teduglutide dose from both studies ("total teduglutide").
Report a problemFND-3788961902
03HumanNon-randomized trialEfficacy outcome
In children receiving teduglutide, enteral nutrition increased by 9.2 and 9.6 mL/kg/day at weeks 12 and 24, respectively.
In plain wordsIn children receiving teduglutide, gut-delivered nutrition increased from baseline at weeks 12 and 24.
Peptide
Teduglutide
Outcome
IncreaseEnteral nutrition at weeks 12 and 24
Study
n = 87
Outcome group
Enteral Nutrition · Gastrointestinal
Studied dose
Dose not stated
Measurements
Enteral volume change
9.2 mL/kg/day
week 12
SE
1.7 mL/kg/day
week 12
Enteral volume change
9.6 mL/kg/day
week 24
SE
2.3 mL/kg/day
week 24
Source sentences
Summary
and enteral nutrition volume [9.2 (1.7; P < 0.0001) and 9.6 (2.3; P = 0.0002) mL/kg/day, respectively].
2 context sentences(design, population, supporting numbers)
Summary · context
Data from 2 open-label, multicenter, phase 3 pediatric SBS-IF clinical trials of teduglutide (NCT01952080 and NCT02682381) were pooled where possible.
Summary · context
The primary objective was to evaluate the change in stool consistency, frequency, and volume from baseline to weeks 12 and 24 of treatment in patients who received any teduglutide dose from both studies ("total teduglutide").
Report a problemFND-3788961903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02682381

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Shiren = 5923 Jun 2016 to 18 Aug 2017

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 9 Jun 2021

CompletedPhase 3Results postedNCT01952080

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

Shiren = 4214 Nov 2013 to 9 Jan 2015

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 9 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.